Role of endothelial nitric oxide synthase in diabetic nephropathy: Lessons from diabetic eNOS knockout mice

Journal of Diabetes Research

Volumn 2014, Issue , 2014, Pages

  Takahashi, Takamune ^a   Harris, Raymond C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FERRITIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; HYDRALAZINE PLUS HYDROCHLOROTHIAZIDE PLUS RESERPINE; LOSARTAN; NITROGEN OXIDE; SPIRONOLACTONE; STREPTOZOCIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; VASCULOTROPIN; NOS3 PROTEIN, MOUSE;

ALBUMINURIA; ANGIOGENESIS; ANTIHYPERTENSIVE THERAPY; BLOOD CLOTTING; CLINICAL FEATURE; DIABETIC NEPHROPATHY; GENE EXPRESSION; GLOMERULOPATHY; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HYALINE DEGENERATION; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY HYPERTROPHY; KIDNEY INJURY; KNOCKOUT MOUSE; MESANGIUM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PATHOGENESIS; PODOCYTE; PODOCYTOPATHY; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; ANIMAL; CHRONIC KIDNEY FAILURE; DEFICIENCY; DISEASE COURSE; DISEASE MODEL; ENZYMOLOGY; GENETICS; GENOTYPE; KIDNEY; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE;

ALBUMINURIA; ANIMALS; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENOTYPE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE III; PHENOTYPE;

EID: 84908326283     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2014/590541     Document Type: Review

References (105)

1. Breyer M. D., Böttinger E., Brosius F. C. III, Coffman T. M., Harris R. C., Heilig C. W., Sharma K., Mouse models of diabetic nephropathy. Journal of the American Society of Nephrology 2005 16 1 27 45 10.1681/ASN.2004080648 2-s2.0-21644463370
2. Xu J., Zou M.-H., Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation 2009 120 13 1266 1286 10.1161/CIRCULATIONAHA.108.835223 2-s2.0-70349675632
3. Rask-Madsen C., King G. L., Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nature Clinical Practice Endocrinology and Metabolism 2007 3 1 46 56 2-s2.0-33845742185 10.1038/ncpendmet0366
4. Versari D., Daghini E., Virdis A., Ghiadoni L., Taddei S., Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009 32 supplement 2 S314 S321 2-s2.0-75549083692 10.2337/dc09-S330
5. Albrecht E. W. J. A., Stegeman C. A., Heeringa P., Henning R. H., van Goor H., Protective role of endothelial nitric oxide synthase. Journal of Pathology 2003 199 1 8 17 10.1002/path.1250 2-s2.0-0037218970
6. Bachmann S., Bosse H. M., Mundel P., Topography of nitric oxide synthesis by localizing constitutive NO synthases in mammalian kidney. The American Journal of Physiology-Renal Fluid and Electrolyte Physiology 1995 268 5 F885 F898 2-s2.0-0029059859
7. Han K.-H., Lim J.-M., Kim W.-Y., Kim H., Madsen K. M., Kim J., Expression of endothelial nitric oxide synthase in developing rat kidney. American Journal of Physiology: Renal Physiology 2005 288 4 F694 F702 10.1152/ajprenal.00085.2004 2-s2.0-15044338895
8. Chu S., Bohlen H. G., High concentration of glucose inhibits glomerular endothelial eNOS through a PKC mechanism. American Journal of Physiology: Renal Physiology 2004 287 3 F384 F392 10.1152/ajprenal.00006.2004 2-s2.0-4143054534
9. Choi K. C., Kim N. H., An M. R., Kang D. G., Kim S. W., Lee J., Alterations of intrarenal renin-angiotensin and nitric oxide systems in streptozotocin-induced diabetic rats. Kidney international. Supplement 1997 60 S23 27 2-s2.0-0003131164
10. Sugimoto H., Shikata K., Matsuda M., Kushiro M., Hayashi Y., Hiragushi K., Wada J., Makino H., Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 1998 41 12 1426 1434 2-s2.0-0031773118 10.1007/s001250051088
11. Veelken R., Hilgers K. F., Hartner A., Haas A., Böhmer K. P., Sterzel R. B., Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. Journal of the American Society of Nephrology 2000 11 1 71 79 2-s2.0-0033982133
12. Wang Y. X., Brooks D. P., Edwards R. M., Attenuated glomerular cGMP production and renal vasodilation in streptozotocin-induced diabetic rats. The American Journal of Physiology-Regulatory Integrative and Comparative Physiology 1993 264 5 R952 R956 2-s2.0-0027233703
13. Craven P. A., Studer R. K., DeRubertis F. R., Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats. Evidence for protein kinase C-mediated suppression of the cholinergic response. Journal of Clinical Investigation 1994 93 1 311 320 10.1172/JCI116961 2-s2.0-0028039015
14. Craven P. A., Studer R. K., DeRubertis F. R., Impaired nitric oxide release by glomeruli from diabetic rats. Metabolism 1995 44 6 695 698 10.1016/0026-0495(95)90178-7 2-s2.0-0029075671
15. Satoh M., Fujimoto S., Haruna Y., Arakawa S., Horike H., Komai N., Sasaki T., Tsujioka K., Makino H., Kashihara N., NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. American Journal of Physiology-Renal Physiology 2005 288 6 F1144 F1152 2-s2.0-21044436751 10.1152/ajprenal.00221.2004
16. Pieper G. M., Enhanced, unaltered and impaired nitric oxide-mediated endothelium- dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia 1999 42 2 204 213 10.1007/s001250051140 2-s2.0-0032950298
17. Yuzawa Y., Niki I., Kosugi T., Maruyama S., Yoshida F., Takeda M., Tagawa Y., Kaneko Y., Kimura T., Kato N., Yamamoto J., Sato W., Nakagawa T., Matsuo S., Overexpression of calmodulin in pancreatic β cells induces diabetic nephropathy. Journal of the American Society of Nephrology 2008 19 9 1701 1711 10.1681/ASN.2006121358 2-s2.0-54749108433
18. Prabhakar S., Starnes J., Shi S., Lonis B., Tran R., Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. Journal of the American Society of Nephrology 2007 18 11 2945 2952 2-s2.0-35848956112 10.1681/ASN.2006080895
19. Tolins J. P., Shultz P. J., Raij L., Brown D. M., Mauer S. M., Abnormal renal hemodynamic response to reduced renal perfusion pressure in diabetic rats: role of NO. American Journal of Physiology 1993 265 6 F886 F895 2-s2.0-0027132286
20. Bank N., Aynedjian H. S., Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney International 1993 43 6 1306 1312 10.1038/ki.1993.183 2-s2.0-0027311108
21. Kamijo H., Higuchi M., Hora K., Chronic inhibition of nitric oxide production aggravates diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty rats. Nephron Physiology 2006 104 1 p12 p22 10.1159/000093276 2-s2.0-33747277744
22. Hiragushi K., Sugimoto H., Shikata K., Yamashita T., Miyatake N., Shikata Y., Wada J., Kumagai I., Fukushima M., Makino H., Nitric oxide system is involved in glomerular hyperfiltration in Japanese normo- and micro-albuminuric patients with type 2 diabetes. Diabetes Research and Clinical Practice 2001 53 3 149 159 10.1016/S0168-8227(01)00260-1 2-s2.0-0034898883
23. Hohenstein B., Hugo C. P. M., Hausknecht B., Boehmer K. P., Riess R. H., Schmieder R. E., Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy. Nephrology Dialysis Transplantation 2008 23 4 1346 1354 2-s2.0-42949117941 10.1093/ndt/gfm797
24. O'Byrne S., Forte P., Roberts L. J. II, Morrow J. D., Johnston A., Änggård E., Leslie R. D. G., Benjamin N., Nitric oxide synthesis and isoprostane production in subjects with type 1 diabetes and normal urinary albumin excretion. Diabetes 2000 49 5 857 862 10.2337/diabetes.49.5.857 2-s2.0-0034033617
25. Chiarelli F., Cipollone F., Romano F., Tumini S., Costantini F., Di Ricco L., Pomilio M., Pierdomenico S. D., Marini M., Cuccurullo F., Mezzetti A., Increased circulating nitric oxide in young patinets with type 1 diabetes and persistent microalbuminuria: relation to glomerular hyperfiltration. Diabetes 2000 49 7 1258 1263 2-s2.0-0033946110 10.2337/diabetes.49.7.1258
26. Apakkan Aksun S., Özmen B., Özmen D., Parildar Z., Şenol B., Habif S., Mutaf I., Turgan N., Bayindir O., Serum and urinary nitric oxide in Type 2 diabetes with or without microalbuminuria: relation to glomerular hyperfiltration. Journal of Diabetes and its Complications 2003 17 6 343 348 10.1016/S1056-8727(02)00196-4 2-s2.0-0142138128
27. Maejima K., Nakano S., Himeno M., Tsuda S.-I., Makiishi H., Ito T., Nakagawa A., Kigoshi T., Ishibashi T., Nishio M., Uchida K., Increased basal levels of plasma nitric oxide in Type 2 diabetic subjects: relationship to microvascular complications. Journal of Diabetes and its Complications 2001 15 3 135 143 10.1016/S1056-8727(01)00144-1 2-s2.0-0035006350
28. Earle K. A., Mehrotra S., Dalton R. N., Denver E., Swaminathan R., Defective nitric oxide production and functional renal reserve in patients with type 2 diabetes who have microalbuminuria of African and Asian compared with white origin. Journal of the American Society of Nephrology 2001 12 10 2125 2130 2-s2.0-0034830352
29. Zanchi A., Moczulski D. K., Hanna L. S., Wantman M., Warram J. H., Krolewski A. S., Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney International 2000 57 2 405 413 10.1046/j.1523-1755.2000.00860.x 2-s2.0-0033917346
30. Noiri E., Satoh H., Taguchi J.-I., Brodsky S. V., Nakao A., Ogawa Y., Nishijima S., Yokomizo T., Tokunaga K., Fujita T., Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension 2002 40 4 535 540 10.1161/01.HYP.0000033974.57407.82 2-s2.0-0036791822
31. Takahashi T., Harris R. C., Prabhakar S. S., Endothelial dysfunction in diabetic nephropathy. Advances in the Pathogenesis of Diabetic Nephropathy 2011 New York, NY, USA Nova Science Publishers
32. Kanetsuna Y., Takahashi K., Nagata M., Gannon M. A., Breyer M. D., Harris R. C., Takahashi T., Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. The American Journal of Pathology 2007 170 5 1473 1484 10.2353/ajpath.2007.060481 2-s2.0-34250816918
33. Nakagawa T., Sato W., Glushakova O., Heinig M., Clarke T., Campbell-Thompson M., Yuzawa Y., Atkinson M. A., Johnson R. J., Croker B., Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. Journal of the American Society of Nephrology 2007 18 2 539 550 10.1681/ASN.2006050459 2-s2.0-33846701668
34. Li F., Wang C.-H., Wang J.-G., Thai T., Boysen G., Xu L., Turner A. L., Wolberg A. S., Mackman N., Maeda N., Takahashi N., Elevated tissue factor expression contributes to exacerbated diabetic nephropathy in mice lacking eNOS fed a high fat diet. Journal of Thrombosis and Haemostasis 2010 8 10 2122 2132 10.1111/j.1538-7836.2010.03976.x 2-s2.0-78649387522
35. Wang C.-H., Li F., Hiller S., Kim H.-S., Maeda N., Smithies O., Takahashi N., A modest decrease in endothelial NOS in mice comparable to that associated with human NOS3 variants exacerbates diabetic nephropathy. Proceedings of the National Academy of Sciences of the United States of America 2011 108 8 2070 2075 10.1073/pnas.1101346108 2-s2.0-79952742822
36. Zhao H. J., Wang S., Cheng H., Zhang M.-Z., Takahashi T., Fogo A. B., Breyer M. D., Harris R. C., Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. Journal of the American Society of Nephrology 2006 17 10 2664 2669 10.1681/ASN.2006070798 2-s2.0-33749236623
37. Mohan S., Reddick R. L., Musi N., Horn D. A., Yan B., Prihoda T. J., Natarajan M., Abboud-Werner S. L., Diabetic eNOS knockout mice develop distinct macro- and microvascular complications. Laboratory Investigation 2008 88 5 515 528 10.1038/labinvest.2008.23 2-s2.0-42549103718
38. Shesely E. G., Maeda N., Kim H.-S., Desai K. M., Krege J. H., Laubach V. E., Sherman P. A., Sessa W. C., Smithies O., Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proceedings of the National Academy of Sciences of the United States of America 1996 93 23 13176 13181 2-s2.0-0029825613 10.1073/pnas.93.23.13176
39. Yuen D. A., Stead B. E., Zhang Y., White K. E., Kabir M. G., Thai K., Advani S. L., Connelly K. A., Takano T., Zhu L., Cox A. J., Kelly D. J., Gibson I. W., Takahashi T., Harris R. C., Advani A., eNOS deficiency predisposes podocytes to injury in diabetes. Journal of the American Society of Nephrology 2012 23 11 1810 1823 10.1681/ASN.2011121170 2-s2.0-84868628539
40. Lin M., Yiu W. H., Li R. X., Wu H. J., Wong D. W. L., Chan L. Y. Y., Leung J. C. K., Lai K. N., Tang S. C. W., The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy. Kidney International 2013 83 5 887 900 10.1038/ki.2013.11 2-s2.0-84877048917
41. Zhang M.-Z., Wang S., Yang S., Yang H., Fan X., Takahashi T., Harris R. C., Role of blood pressure and the renin-angiotensin system in development of diabetic nephropathy (DN) in eNOS-/-db/db mice. The American Journal of Physiology: Renal Physiology 2012 302 4 F433 F438 10.1152/ajprenal.00292.2011 2-s2.0-84863022503
42. Sato W., Kosugi T., Zhang L., Roncal C. A., Heinig M., Campbell-Thompson M., Yuzawa Y., Atkinson M. A., Grant M. B., Croker B. P., Nakagawa T., The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy. Laboratory Investigation 2008 88 9 949 961 10.1038/labinvest.2008.60 2-s2.0-50249148344
43. Tanabe K., Lanaspa M. A., Kitagawa W., Rivard C. J., Miyazaki M., Klawitter J., Schreiner G. F., Saleem M. A., Mathieson P. W., Makino H., Johnson R. J., Nakagawa T., Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse. The American Journal of Physiology-Renal Physiology 2012 302 9 F1151 F1160 10.1152/ajprenal.00596.2011 2-s2.0-84860540851
44. Kosugi T., Heinig M., Nakayama T., Connor T., Yuzawa Y., Li Q., Hauswirth W. W., Grant M. B., Croker B. P., Campbell-Thompson M., Zhang L., Atkinson M. A., Segal M. S., Nakagawa T., Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice. The American Journal of Pathology 2009 174 4 1221 1229 2-s2.0-65349142464 10.2353/ajpath.2009.080605
45. Huang C., Shen S., Ma Q., Chen J., Gill A., Pollock C. A., Chen X.-M., Blockade of KCa3.1 ameliorates renal fibrosis through the tgf- β 1/smad pathway in diabetic mice. Diabetes 2013 62 8 2923 2934 10.2337/db13-0135 2-s2.0-84885407930
46. Kosugi T., Heinig M., Nakayama T., Matsuo S., Nakagawa T., eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists. The American Journal of Pathology 2010 176 2 619 629 10.2353/ajpath.2010.090578 2-s2.0-76149086524
47. Li G., Barrett E. J., Ko S.-H., Cao W., Liu Z., Insulin and insulin-like growth factor-I receptors differentially mediate insulin-stimulated adhesion molecule production by endothelial cells. Endocrinology 2009 150 8 3475 3482 2-s2.0-67651177695 10.1210/en.2009-0172
48. Madonna R., Pandolfi A., Massaro M., Consoli A., de Caterina R., Insulin enhances vascular cell adhesion molecule-1 expression in human cultured endothelial cells through a pro-atherogenic pathway mediated by p38 mitogen-activated protein-kinase. Diabetologia 2004 47 3 532 536 10.1007/s00125-004-1330-x 2-s2.0-1842844426
49. Nordt T. K., Sawa H., Fujii S., Bode C., Sobel B. E., Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo. Journal of Molecular and Cellular Cardiology 1998 30 8 1535 1543 10.1006/jmcc.1998.0719 2-s2.0-0032143386
50. Nacci C., Tarquinio M., Montagnani M., Molecular and clinical aspects of endothelial dysfunction in diabetes. Internal and Emergency Medicine 2009 4 2 107 116 10.1007/s11739-009-0234-7 2-s2.0-62949133518
51. Qi Z., Fujita H., Jin J., Davis L. S., Wang Y., Fogo A. B., Breyer M. D., Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 2005 54 9 2628 2637 10.2337/diabetes.54.9.2628 2-s2.0-24144496134
52. Gurley S. B., Clare S. E., Snow K. P., Hu A., Meyer T. W., Coffman T. M., Impact of genetic background on nephropathy in diabetic mice. American Journal of Physiology: Renal Physiology 2006 290 1 F214 F222 10.1152/ajprenal.00204.2005 2-s2.0-33644802764
53. Zhang M.-Z., Wang Y., Paueksakon P., Harris R. C., Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy. Diabetes 2014 63 6 2063 2072 10.2337/db13-1279 2-s2.0-84901367130
54. Nasrallah M. P., Ziyadeh F. N., Overview of the physiology and pathophysiology of leptin with special emphasis on its role in the kidney. Seminars in Nephrology 2013 33 1 54 65 10.1016/j.semnephrol.2012.12.005 2-s2.0-84873193797
55. Schnedl W. J., Ferber S., Johnson J. H., Newgard C. B., STZ transport and cytotoxicity: specific enhancement in GLUT2-expressing cells. Diabetes 1994 43 11 1326 1333 2-s2.0-0028604486 10.2337/diab.43.11.1326
56. Schmezer P., Eckert C., Liegibel U. M., Tissue-specific induction of mutations by streptozotocin in vivo. Mutation Research 1994 307 2 495 499 2-s2.0-0028271775 10.1016/0027-5107(94)90260-7
57. Imaeda A., Kaneko T., Aoki T., Kondo Y., Nagase H., DNA damage and the effect of antioxidants in streptozotocin-treated mice. Food and Chemical Toxicology 2002 40 7 979 987 2-s2.0-0036285710 10.1016/S0278-6915(02)00014-5
58. Inada A., Kanamori H., Arai H., Akashi T., Araki M., Weir G. C., Fukatsu A., A model for diabetic nephropathy: advantages of the inducible cAMP early repressor transgenic mouse over the streptozotocin-induced diabetic mouse. Journal of Cellular Physiology 2008 215 2 383 391 10.1002/jcp.21316 2-s2.0-40949101317
59. Koulmanda M., Qipo A., Chebrolu S., O'Neil J., Auchincloss H. Jr., Smith R. N., The effect of low versus high dose of streptozotocin in cynomolgus monkeys (Macaca fascilularis). The American Journal of Transplantation 2003 3 3 267 272 10.1034/j.1600-6143.2003.00040.x 2-s2.0-0037355040
60. Tantawy M. N., Jiang R., Wang F., Takahashi K., Peterson T. E., Zemel D., Hao C.-M., Fujita H., Harris R. C., Quarles C. C., Takahashi T., Assessment of renal function in mice with unilateral ureteral obstruction using 99mTc-MAG3 dynamic scintigraphy. BMC Nephrology 2012 13 1, article 168 2-s2.0-84872134481 10.1186/1471-2369-13-168
61. Rask-Madsen C., Kahn C. R., Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2012 32 9 2052 2059 10.1161/ATVBAHA.111.241919 2-s2.0-84865472821
62. Ho F. M., Lin W. W., Chen B. C., Chao C. M., Yang C.-R., Lin L. Y., Lai C. C., Liu S. H., Liau C. S., High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF- B and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway. Cellular Signalling 2006 18 3 391 399 2-s2.0-27844593740 10.1016/j.cellsig.2005.05.009
63. Peng H.-B., Libby P., Liao J. K., Induction and stabilization of I B α by nitric oxide mediates inhibition of NF- B. The Journal of Biological Chemistry 1995 270 23 14214 14219 10.1074/jbc.270.23.14214 2-s2.0-0029011129
64. De Caterina R., Libby P., Peng H.-B., Thannickal V. J., Rajavashisth T. B., Gimbrone M. A. Jr., Shin W. S., Liao J. K., Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. The Journal of Clinical Investigation 1995 96 1 60 68 10.1172/JCI118074 2-s2.0-0029159779
65. Peng H.-B., Rajavashisth T. B., Libby P., Liao J. K., Nitric oxide inhibits macrophage-colony stimulating factor gene transcription in vascular endothelial cells. The Journal of Biological Chemistry 1995 270 28 17050 17055 2-s2.0-0029043048 10.1074/jbc.270.28.17050
66. Studer R. K., DeRubertis F. R., Craven P. A., Nitric oxide suppresses increases in mesangial cell protein kinase C, transforming growth factor β and fibronectin synthesis induced by thromboxane. Journal of the American Society of Nephrology 1996 7 7 999 1005 2-s2.0-0030363782
67. Papapetropoulos A., García-Cardeña G., Madri J. A., Sessa W. C., Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. Journal of Clinical Investigation 1997 100 12 3131 3139 10.1172/JCI119868 2-s2.0-2642597076
68. Patzak A., Lai E., Persson P. B., Persson A. E. G., Angiotensin II-nitric oxide interaction in glomerular arterioles. Clinical and Experimental Pharmacology and Physiology 2005 32 5-6 410 414 10.1111/j.1440-1681.2005.04203.x 2-s2.0-20344361996
69. Bidani A. K., Polichnowski A. J., Loutzenhiser R., Griffin K. A., Renal microvascular dysfunction, hypertension and CKD progression. Current Opinion in Nephrology and Hypertension 2013 22 1 1 9 10.1097/MNH.0b013e32835b36c1 2-s2.0-84871733181
70. Nakagawa T., Kosugi T., Haneda M., Rivard C. J., Long D. A., Abnormal angiogenesis in diabetic nephropathy. Diabetes 2009 58 7 1471 1478 10.2337/db09-0119 2-s2.0-67650236579
71. Maeshima Y., Makino H., Angiogenesis and chronic kidney disease. Fibrogenesis & Tissue Repair 2010 3, article 13 10.1186/1755-1536-3-13
72. Nakagawa T., Sato W., Sautin Y. Y., Glushakova O., Croker B., Atkinson M. A., Tisher C. C., Johnson R. J., Uncoupling of vascular endothelial growth factor with nitric oxide as a mechanism for diabetic vasculopathy. Journal of the American Society of Nephrology 2006 17 3 736 745 10.1681/ASN.2005070759 2-s2.0-33645456312
73. Nakagawa T., Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. American Journal of Physiology-Renal Physiology 2007 292 6 F1665 F1672 2-s2.0-34447625374 10.1152/ajprenal.00495.2006
74. Veron D., Aggarwal P. K., Velazquez H., Kashgarian M., Moeckel G., Tufro A., Podocyte-specific VEGF-A gain of function induces nodular glomerulosclerosis in eNOS null mice. Journal of the American Society of Nephrology 2014 25 8 1814 1824 10.1681/ASN.2013070752
75. Fukumura D., Gohongi T., Kadambi A., Izumi Y., Ang J., Yun C.-O., Buerk D. G., Huang P. L., Jain R. K., Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proceedings of the National Academy of Sciences of the United States of America 2001 98 5 2604 2609 2-s2.0-0035956947 10.1073/pnas.041359198
76. Babaei S., Teichert-Kuliszewska K., Zhang Q., Jones N., Dumont D. J., Stewart D. J., Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide. American Journal of Pathology 2003 162 6 1927 1936 10.1016/S0002-9440(10)64326-X 2-s2.0-0038243865
77. Kashiwagi S., Izumi Y., Gohongi T., Demou Z. N., Xu L., Huang P. L., Buerk D. G., Munn L. L., Jain R. K., Fukumura D., NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. The Journal of Clinical Investigation 2005 115 7 1816 1827 10.1172/JCI24015 2-s2.0-22144456034
78. Grutzmacher C., Park S., Zhao Y., Morrison M. E., Sheibani N., Sorenson C. M., Aberrant production of extracellular matrix proteins and dysfunction in kidney endothelial cells with a short duration of diabetes. The American Journal of Physiology-Renal Physiology 2013 304 1 F19 F30 10.1152/ajprenal.00036.2012 2-s2.0-84871867918
79. Salmon A. H., Satchell S. C., Endothelial glycocalyx dysfunction in disease: albuminuria and increased microvascular permeability. The Journal of Pathology 2012 226 4 562 574 10.1002/path.3964 2-s2.0-84856708866
80. Arcos M. I., Fujihara C. K., Sesso A., de Almeida Prado E. B., de Almeida Prado M. J., de Nucci G., Zatz R., Mechanisms of albuminuria in the chronic nitric oxide inhibition model. The American Journal of Physiology-Renal Physiology 2000 279 6 F1060 F1066 2-s2.0-15444369014
81. Bennett K. M., Bertram J. F., Beeman S. C., Gretz N., The emerging role of MRI in quantitative renal glomerular morphology. American Journal of Physiology-Renal Physiology 2013 304 10 F1252 F1257 10.1152/ajprenal.00714.2012 2-s2.0-84878636182
82. Singh A., Satchell S. C., Neal C. R., McKenzie E. A., Tooke J. E., Mathieson P. W., Glomerular endothelial glycocalyx constitutes a barrier to protein permeability. Journal of the American Society of Nephrology 2007 18 11 2885 2893 10.1681/ASN.2007010119 2-s2.0-35848940725
83. Gil N., Goldberg R., Neuman T., Garsen M., Zcharia E., Rubinstein A. M., van Kuppevelt T., Meirovitz A., Pisano C., Li J.-P., van der Vlag J., Vlodavsky I., Elkin M., Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes 2012 61 1 208 216 10.2337/db11-1024 2-s2.0-84555188487
84. Wijnhoven T. J. M., van den Hoven M. J. W., Ding H., van Kuppevelt T. H., van der Vlag J., Berden J. H. M., Prinz R. A., Lewis E. J., Schwartz M., Xu X., Heparanase induces a differential loss of heparan sulphate domains in overt diabetic nephropathy. Diabetologia 2008 51 2 372 382 10.1007/s00125-007-0879-6 2-s2.0-37548999851
85. Miyazawa T., Zeng F., Wang S., Fan X., Cheng H., Yang H., Bian A., Fogo A. B., Harris R. C., Low nitric oxide bioavailability upregulates renal heparin binding EGF-like growth factor expression. Kidney International 2013 84 6 1176 1188 10.1038/ki.2013.214 2-s2.0-84888636933
86. Nakayama T., Sato W., Yoshimura A., Zhang L., Kosugi T., Campbell-Thompson M., Kojima H., Croker B. P., Nakagawa T., Endothelial von Willebrand factor release due to eNOS deficiency predisposes to thrombotic microangiopathy in mouse aging kidney. The American Journal of Pathology 2010 176 5 2198 2208 10.2353/ajpath.2010.090316 2-s2.0-77952071017
87. Ho D. J. J., Jeffrey Man H. S., Marsden P. A., Nitric oxide signaling in hypoxia. Journal of Molecular Medicine 2012 90 3 217 231 10.1007/s00109-012-0880-5 2-s2.0-84862530396
88. Olson N., van der Vliet A., Interactions between nitric oxide and hypoxia-inducible factor signaling pathways in inflammatory disease. Nitric Oxide-Biology and Chemistry 2011 25 2 125 137 10.1016/j.niox.2010.12.010 2-s2.0-80051549232
89. Khan S., Jawdeh B. G. A., Goel M., Schilling W. P., Parker M. D., Puchowicz M. A., Yadav S. P., Harris R. C., El-Meanawy A., Hoshi M., Shinlapawittayatorn K., Deschênes I., Ficker E., Schelling J. R., Lipotoxic disruption of NHE1 interaction with PI(4,5)P2 expedites proximal tubule apoptosis. Journal of Clinical Investigation 2014 124 3 1057 1068 10.1172/JCI71863 2-s2.0-84896766836
90. Hodgin J. B., Nair V., Zhang H., Randolph A., Harris R. C., Nelson R. G., Weil E. J., Cavalcoli J. D., Patel J. M., Brosius F. C. III, Kretzler M., Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. Diabetes 2013 62 1 299 308 10.2337/db11-1667 2-s2.0-84872047522
91. Baelde H. J., Eikmans M., Lappin D. W. P., Doran P. P., Hohenadel D., Brinkkoetter P.-T., Van Der Woude F. J., Waldherr R., Rabelink T. J., De Heer E., Bruijn J. A., Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney International 2007 71 7 637 645 10.1038/sj.ki.5002101 2-s2.0-33846669530
92. Doublier S., Salvidio G., Lupia E., Ruotsalainen V., Verzola D., Deferrari G., Camussi G., Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003 52 4 1023 1030 10.2337/diabetes.52.4.1023 2-s2.0-0345505674
93. Toyoda M., Najafian B., Kim Y., Caramori M. L., Mauer M., Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 2007 56 8 2155 2160 2-s2.0-34547611903 10.2337/db07-0019
94. Moncada S., Higgs E. A., The discovery of nitric oxide and its role in vascular biology. British Journal of Pharmacology 2006 147 S1 S193 S201 10.1038/sj.bjp.0706458 2-s2.0-30444439216
95. Brookes P., Darley-Usmar V. M., Hypothesis: The mitochondrial NO·signaling pathway, and the transduction of nitrosative to oxidative cell signals: an alternative function for cytochrome c oxidase. Free Radical Biology and Medicine 2002 32 4 370 374 10.1016/S0891-5849(01)00805-X 2-s2.0-0037082357
96. +/C96Y (Akita) mice. American Journal of Physiology-Renal Physiology 2010 298 3 F788 F795 10.1152/ajprenal.90515.2008
97. Duplain H., Burcelin R, Sartori C., Cook S., Egli M., Lepori M., Vollenweider P., Pedrazzini T., Nicod P., Thorens B., Scherrer U., Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 2001 104 3 342 345 10.1161/01.CIR.104.3.342 2-s2.0-0035902547
98. Hsu M.-F., Meng T.-C., Enhancement of insulin responsiveness by nitric oxide-mediated inactivation of protein-tyrosine phosphatases. Journal of Biological Chemistry 2010 285 11 7919 7928 10.1074/jbc.M109.057513 2-s2.0-77950890821
99. Feng Q., Song W., Lu X., Hamilton J. A., Lei M., Peng T., Yee S.-P., Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase. Circulation 2002 106 7 873 879 10.1161/01.CIR.0000024114.82981.EA 2-s2.0-0037072469
100. Lee T. C., Zhao Y. D., Courtman D. W., Stewart D. J., Abnormal aortic valve development in mice lacking endothelial nitric oxide synthase. Circulation 2000 101 20 2345 2348 10.1161/01.CIR.101.20.2345 2-s2.0-0034704998
101. Han R. N. N., Babaei S., Robb M., Lee T., Ridsdale R., Ackerley C., Post M., Stewart D. J., Defective lung vascular development and fatal respiratory distress in endothelial NO synthase-deficient mice: a model of alveolar capillary dysplasia? Circulation Research 2004 94 8 1115 1123 10.1161/01.RES.0000125624.85852.1E 2-s2.0-2342613573
102. Forbes M. S., Thornhill B. A., Park M. H., Chevalier R. L., Lack of endothelial nitric-oxide synthase leads to progressive focal renal injury. The American Journal of Pathology 2007 170 1 87 99 2-s2.0-33847043625 10.2353/ajpath.2007.060610
103. Li H., Wallerath T., Förstermann U., Physiological mechanisms regulating the expression of endothelial-type NO synthase. Nitric Oxide-Biology and Chemistry 2002 7 2 132 147 10.1016/S1089-8603(02)00127-1 2-s2.0-0036751127
104. Kleinbongard P., Schulz R., Rassaf T., Lauer T., Dejam A., Jax T., Kumara I., Gharini P., Kabanova S., Özüyaman B., Schnürch H.-G., Gödecke A., Weber A.-A., Robenek M., Robenek H., Bloch W., Rösen P., Kelm M., Red blood cells express a functional endothelial nitric oxide synthase. Blood 2006 107 7 2943 2951 10.1182/blood-2005-10-3992 2-s2.0-33645532445
105. Jiang R., Wang S., Takahashi K., Fujita H., Fruci C. R., Breyer M. D., Harris R. C., Takahashi T., Generation of a conditional allele for the mouse endothelial nitric oxide synthase gene. Genesis 2012 50 9 685 692 10.1002/dvg.22026 2-s2.0-84866597899